Pharmacy benefit managers: a mechanism for containing costs or a contributor to rising drug prices?

While pharmaceutical companies are often the focus of conversations about high drug prices, more recently pharmacy benefit managers (PBMs) have come under increased drug price scrutiny. The American PBM business model, developed in the early 2000s, was designed to identify… Continue Reading

CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America

Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading

Job Market for HEOR & Market Access: Success Strategies

The job market for HEOR, Market Access, Medical Affairs, and Real World Evidence is as hot as an Arizona airport jetway! There is no shortage of jobs for individuals with skills in health economics, outcomes research, value assessment, informatics and… Continue Reading

Industry Groups Challenge Readiness of ICER’s Value Framework

Healthcare is all about making decisions. Who to treat? When to treat? How to treat? How long to treat? How much to spend to treat? The list goes on and on. Fortunately, great strides have been made in healthcare decision… Continue Reading

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing.  The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading